Ignota Labs - About the company
Ignota Labs is a seed company based in London (United Kingdom), founded in 2021 by Layla Hosseini-Gerami and Sam Windsor. It operates as an AI-driven toxicity prediction tools for early-stage drug discovery scientists. Ignota Labs has raised $6.9M in funding from Montage Ventures and AIX Ventures. The company has 3574 active competitors, including 1235 funded and 854 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Ignota Labs is a technology startup in the pharmaceutical sector that provides AI-driven toxicity prediction tools for early-stage drug discovery scientists. Their suite of tools, TOXSCAPE, helps scientists identify and understand safety issues during the drug discovery process, reducing expensive setbacks and delays.
- Website
- www.ignotalabs.ai/
- Email ID
- *****@ignotalabs.ai
- Registered Address
- 5TH FLOOR COUNTY HALL,,WESTMINSTER BRIDGE ROAD,LONDON,ENGLAND,SE1 7PB
Key Metrics
Founded Year
2021
Location
London, United Kingdom
Stage
Seed
Total Funding
$6.9M in 1 round
Latest Funding Round
Investors
Ranked
626th among 3574 active competitors
Employee Count
23 as on Apr 30, 2026
Legal entities associated with Ignota Labs
Ignota Labs is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
ABSOLUTEAI LTD CIN: 13678972 , United Kingdom, Active | Oct 13, 2021 | - | 6 (As on Oct 31, 2024) |
Sign up to download Ignota Labs' company profile
Ignota Labs's funding and investors
Ignota Labs has raised a total funding of $6.9M over 1 round. Its latest funding round was a Seed round on Feb 26, 2025 for $*****. 6 investors participated in its latest round. Ignota Labs has 8 institutional investors.
Here is the list of recent funding rounds of Ignota Labs:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Feb 26, 2025 | 7605740 | Seed | 3415130 | 2462534 | 7743772 | 4864277 |
Access funding benchmarks and valuations. Sign up today!View details of Ignota Labs's funding rounds and investors
Ignota Labs' founders and board of directors
Founder? Claim ProfileThe founders of Ignota Labs are Layla Hosseini-Gerami and Sam Windsor. Sam Windsor and Jordan Lane are the CEOs of Ignota Labs.
Here are the details of Ignota Labs' key team members:
- Layla Hosseini-Gerami: Co-Founder of Ignota Labs. Contact Info: 1 email address
- Sam Windsor: Co-Founder & Co-CEO of Ignota Labs and founder of 1 other company. Contact Info: 1 email address
- Jordan Lane: Co-CEO of Ignota Labs. Contact Info: 1 email address
View details of Ignota Labs's Founder profiles and Board Members
Ignota Labs' employee count trend
Ignota Labs has 23 employees as of Apr 26. Here is Ignota Labs's employee count trend over the years:
Uncover Ignota Labs' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Ignota Labs's Competitors and alternates
Top competitors of Ignota Labs include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Ignota Labs, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating human disease conditions | $821M | 75/100 | |
4th | Blueprint Medicines 2008, Cambridge (United States), Acquired | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | 72/100 | |
5th | Senti Biosciences 2016, San Francisco (United States), Public | Developer of cell-based therapies for cancer treatment | $158M | 72/100 | |
6th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
7th | _1548135965397.png?devicePixelRatio=2&height=30&width=30){kind=logo} Kronos Bio 2017, San Mateo (United States), Acquired | Developer of small molecule based therapeutics for cancer treatment | $271M | 72/100 | |
8th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
9th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
10th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
626th |  Ignota Labs 2021, London (United Kingdom), Seed | AI-driven toxicity prediction tools for early-stage drug discovery scientists | $6.9M | 52/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Ignota Labs's competitors? Click here to see the top ones
Ignota Labs's Investments and acquisitions
Ignota Labs has made no investments or acquisitions yet.
News related to Ignota Labs
Media has covered Ignota Labs for a total of 2 events in the last 1 year.
•
Ignota Labs Acquires Kronos’s Clinical PipelineBusiness Wire•Oct 06, 2025•Ignota Labs, Kronosww, Kronos
•
London MedTech raises £5.5m to address $400bn annual issueBusinessCloud•Feb 26, 2025•Ignota Labs, Montage Ventures, AIX Ventures, Modi Ventures and 2 others
•
Ignota Labs Secures $6.9M to Bring ‘Dead’ Drugs Back to Life with AISynBioBeta•Feb 26, 2025•Ignota Labs, Montage Ventures, AIX Ventures, Modi Ventures and 2 others
•
Ignota Labs Raises USD $6.9M Seed Funding to Turn Around Failed DrugsBenzinga•Feb 26, 2025•Ignota Labs, Montage Ventures, AIX Ventures, Modi Ventures and 2 others
•
Rescuing drugs: Ignota Labs raises €6.6 million to turn around failed drugsEU-Startups•Feb 26, 2025•Ignota Labs, Montage Ventures, AIX Ventures, Modi Ventures and 2 others
•
UK Ignota Labs Raises USD $6.9M in Seed FundingFinSMEs•Feb 26, 2025•Ignota Labs, Montage Ventures, AIX Ventures, Modi Ventures and 2 others
•
Kent's DPV invests in AbsoluteAi and Oxford Medical ProductsThe Business Magazine•Apr 12, 2023•Discovery Park, Oxford Medical Products, Ignota Labs
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Ignota Labs
Explore our recently published companies
- Medium API - Indore based, 2021 founded, Unfunded company
- Extermis Infotech - Porbandar based, 2018 founded, Unfunded company
- SS Technologies - India based, Unfunded company
- MVS Engineering - Delhi based, 1977 founded, Unfunded company
- MicroNet - Nisswa based, 1996 founded, Unfunded company
- PRIEUR Sports - France based, 1788 founded, Unfunded company
